An update on bronchodilators in Phase I and II clinical trials

Bibliography

• O'Reilly J, Jones MM, Parnham J, Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 2010;340:c3134
   PubMedGoogle Scholar
• National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program. Expert panel report 3 (EPR-3): Guidelines for the diagnosis and management of asthma–summary report 2007. J Allergy Clin Immunol 2007;120(5 Suppl):S94–138
   Google Scholar
• Bateman ED, Hurd SS, Barnes PJ, Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143–78
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008;155:291–9
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009;34:757–69
   PubMed Web of Science ®Google Scholar
• Cazzola M, Segreti A, Matera MG. Novel bronchodilators in asthma. Curr Opin Pulm Med 2010;16:6–12
   PubMed Web of Science ®Google Scholar
• Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32:495–506
   PubMed Web of Science ®Google Scholar
• Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta agonists in the treatment of asthma. N Engl J Med 2010;362:1169–71
   PubMed Web of Science ®Google Scholar
• Young A, Nicholls D, Connolly S, AZD3199: a potent and selective β2-adrenergic receptor agonist with rapid onset of action (Abstract). Am J Respir Crit Care Med 2011;183:A1585
   Google Scholar
• Young A, Nicholls D, Connolly S, The in vivo profile of AZD3199: a novel, fast acting β2-agonist with a long duration of action (Abstract). Am J Respir Crit Care Med 2011;183:A1586
   Google Scholar
• Kuna P, Ivanov Y, Trofimov V, Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD (Abstract). Eur Respir J 2011;38:148s
   Google Scholar
• Li GL, Mac Intyre F, Surujbally B, Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2-adrenoreceptor agonist (Abstract). Eur Respir J 2009;34:777s
   Google Scholar
• Macintyre F, Jones I, Surujbally B. A randomised, double-blind study to determine the duration of action of lung pharmacodynamics by plethysmography (sGaw) of a β2 adrenoreceptor agonist, PF-00610355 (Abstract). Eur Respir J 2009;34:344s
   Google Scholar
• Ward J, Macintyre F, Jones I, A randomised double-blind, study to determine the efficacy & safety of a once-daily inhaled β2 adrenoreceptor agonist, PF-00610355 in asthmatic patients (Abstract). Eur Respir J 2009;34:778s
   PubMed Web of Science ®Google Scholar
• Aparici M, Gomez-Angelats M, Vilella D, Pharmacological characterization of abediterol, a novel inhaled β2 adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. J Pharmacol Exp Ther 2012; DOI:10.1124/jpet.112.193284
   PubMed Web of Science ®Google Scholar
• Timmer W, Massana EJiménez E, Single doses of LAS100977, a novel long acting β2-agonist, show high activity and long duration in healthy subjects (Abstract). Am J Respir Crit Care Med 2010;181:A5663
   Google Scholar
• Beier J, Fuhr R, Massana E, Efficacy and safety of single doses of inhaled LAS100977 in patients with persistent asthma (Abstract). Am J Respir Crit Care Med 2010;181:A5414
   Google Scholar
• Kerstjens HA, Disse B, Schröder-Babo W, Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011;128:308–14
   PubMed Web of Science ®Google Scholar
• Rennard SI, Fogarty C, Ferguson GT, A novel glycopyrrolate metered dose inhaler formulation demonstrates superior bronchodilator efficacy relative to placebo and comparable efficacy and safety to Spiriva® Handihaler® in patients with COPD (Abstract). Am J Resp Crit Care Med 2010;181:A4450
   Google Scholar
• Orevillo C, St Rose E, Strom S, Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomised, double-blind, placebo-controlled phase 2b study in patients with COPD. Eur Respir J 2011;38(Suppl 55):724s
   Google Scholar
• Singh D, Leaker A, Tutuncu A. Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD. Eur Respir J 2011;38(Suppl. 55):147s
   PubMedGoogle Scholar
• Anonymous. Theravance announces positive results from a Phase 2a study of its LAMA candidate, TD-4208, for the treatment of COPD. Available from: http://www.marketwire.com/press-release/theravance-announces-positive-results-from-phase-2a-study-its-lama-candidate-td-4208-nasdaq-thrx-1586645.htm [Last accessed 25 April 2012]
   Google Scholar
• Anonymous. Alkermes and Indevus announce positive results from Phase 2a clinical study of ALKS 27 for the treatment of COPD. Available from: http://www.drugs.com/clinical_trials/alkermes-indevus-announce-positive-results-phase-2a-clinical-study-alks-27-copd-2085.html [Last accessed 25 April 2012]
   Google Scholar
• Oleson L, Turncliff RZ, Silverman B, ALKS 27 (Trospium Inhalation Powder) improves lung function following single administration in subjects with COPD (Abstract). Am J Respir Crit Care Med 2010;181:A4457
   Google Scholar
• Cazzola M, Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23:257–67
   PubMed Web of Science ®Google Scholar
• van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012;21:101–8
   PubMedGoogle Scholar
• Śliwiński P, Perng D-W, Chuchalin A, Jones PW. Efficacy and safety of once-daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD (Abstract). Thorax 2010;65:A136
   Web of Science ®Google Scholar
• Anonymous. Positive results for aclidinium alone and in combination with formoterol. Available from: http://www.oindpnews.com/2011/02/positive-results-for-aclidinium-alone-and-in-combination-with-formoterol/ [Last accessed 27 April, 2012]
   Google Scholar
• Anonymous. Almirall starts Phase III for aclidinium and formoterol in COPD. Available from: http://www.almirall.com/webcorp2/contentFiles/1596/en/AB+For_Phase_III_press_release_final.pdf [Last acessed 27 April, 2012]
   Google Scholar
• Joshi V, Noga B, Lechuga-Ballesteros D, Nanogram level in vitro dose proportionality and stability of glycopyrrolate and formoterol fumarate in a novel cosuspension metered dose inhaler format (Abstract). Am J Respir Crit Care Med 2012;185:A6797
   Google Scholar
• Marjason J, Orevillo C, St Rose E, Assessment of safety and pharmacokinetic profile of a novel fixed combination of glycopyrrolate and formoterol HFA MDI in healthy volunteers (Abstract). Am J Respir Crit Care Med 2010;181:A4455
   Google Scholar
• Reisner C, Fogarty C, Spangenthal S, GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD (Abstract). Am J Resp Crit Care Med 2011;183:A6435
   Web of Science ®Google Scholar
• Reisner C, St.Rose E, Strom A, Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebocontrolled phase 2b study in patients with COPD (Abstract). Eur Respir J 2011;38(Suppl 55):150s
   Google Scholar
• Reisner C, Fernandez C, Orevillo C, Pearl Therapeutics' combination LAMA/LABA MDI (GFF MDI, PT003) provides comparable metabolic and ECG safety to Spiriva® Handihaler® and placebo in patients with COPD (Abstract). Am J Respir Crit Care Med 2012;185:A2925
   Google Scholar
• Feldman G, Walker RR, Brooks J, Safety and tolerability of the umeclidinium bromide/vilanterol combination in patients with COPD (Abstract). Am J Respir Crit Care Med 2012;185:A2938
   Google Scholar
• Steinfeld T, Hughes AD, Klein U, THRX-198321 is a bifunctional muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol 2011;79:389–99
   PubMed Web of Science ®Google Scholar
• Hughes AD, McNamara A, Steinfeld T. Multivalent dual pharmacology muscarinic antagonist and β2 agonist (MABA) molecules for the treatment of COPD. Prog Med Chem 2012;51:71–95
   PubMedGoogle Scholar
• Norris V, Zhu CQ, Ambery C. The pharmacodynamics of GSK961081 in patients with COPD (Abstract). Eur Respir J 2011;38:138s
   Google Scholar
• Mammen M; Theravance. Medicines that make a difference. Available from: http://files.shareholder.com/downloads/THERA/0x0x557313/bbb6e7d0-300d-4435-a974-b294236110ed/Theravance%20Needham%20Presentation.pdf [Last accessed 1 May 2012]
   Google Scholar
• Anonymous. Almirall strengthens its respiratory franchise with a new generation of Chronic Obstructive Pulmonary Disease (COPD) treatment. Available from: http://www.medicalnewstoday.com/articles/222082.php [Last accessed 1 May, 2012]
   Google Scholar
• Maspero JF, Nolte H, Chérrez-Ojeda I. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J Asthma 2010;47:1106–15
   PubMed Web of Science ®Google Scholar
• Norman P. Boehringer Ingleheim's selective glucocorticoid receptor agonist development candidate: evaluation of WO2010141331, WO2010141332 and WO2010141333. Expert Opin Ther Pat 2011;21:1137–42
   PubMed Web of Science ®Google Scholar
• Gaebel K, McIvor RA, Xie F, Triple therapy for the management of COPD: a review. COPD 2011;8:206–43
   PubMedGoogle Scholar
• Jones C, Santanello NC, Boccuzzi SJ, Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma 2003;40:93–101
   PubMed Web of Science ®Google Scholar
• Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994;154:1349–52
   PubMed Web of Science ®Google Scholar
• Rau JL. Determinants of patient adherence to an aerosol regimen. Respir Care 2005;50:1346–56
   PubMedGoogle Scholar
• Toy EL, Beaulieu NU, McHale JM, Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011;105:435–41
   PubMed Web of Science ®Google Scholar
• Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 1999;58(Suppl 4):25–33
   PubMedGoogle Scholar
• Beeh KM, Beier J. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010;27:150–9
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504.
   PubMed Web of Science ®Google Scholar
• Kessler R, Partridge MR, Miravitlles M, Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37:264–72
   PubMed Web of Science ®Google Scholar
• Chung KF, Caramori G, Adcock IM. Inhaled corticosteroids as combination therapy with β-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol 2009;65:853–71
   PubMed Web of Science ®Google Scholar
• Cazzola M, Dahl R. Inhaled combination therapy with long-acting β2-agonists and corticosteroids in stable COPD. Chest 2004;126:220–37
   PubMed Web of Science ®Google Scholar
• Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010;362:1169–71
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA. Safety of long-acting β agonists for the treatment of asthma: clearing the air. Thorax 2012;67:342–9
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Long-acting beta2-adrenoceptor agonist bronchodilators formoterol and salmeterol – review of safety in the management of asthma. Summary Assessment Report of the Pharmacovigilance Working Party. European Medicines Agency; 2010. Available from: www.ema.europa.eu/docs/en_GB/document_library/Report/2010/10/WC500098462.pdf [Last] [accessed 5 June, 2012]
   Google Scholar
• Hurst JR, Vestbo J, Anzueto A, Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128–38
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007(4):CD003794
   Google Scholar